Clinical trialsCompany release
Can-Fite completes dosing in interim cohort of Phase III piclidenoson psoriasis trial
Can-Fite BioPharma Ltd. (CANF) · Wed 18 Nov 2026
The last of the first 247 patients in the pivotal oral piclidenoson study has received the final dose, with an independent committee due to review interim data in Q1 2027.
Can-Fite BioPharma said on 18 November 2026 that dosing is complete for the interim-analysis cohort in its pivotal Phase III study of oral piclidenoson in moderate-to-severe plaque psoriasis. The last of the first 247 patients has received the final dose.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Can-Fite BioPharma Ltd. ↗
Article written by VigiEye from the official source (Can-Fite BioPharma Ltd.). Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
Teleflex recalls PICC kits and spring-wire guides over coating detachment risk, Health Canada reports
🇨🇦 Health Canada · Wed 18 Nov 2026
Health Canada: Raz Design recalls shower commode chairs over seats that can break
🇨🇦 Health Canada · Wed 18 Nov 2026
Summit starts Phase III HARMONi-10 of ivonescimab against durvalumab in Stage III NSCLC
🇺🇸 Summit Therapeutics Inc. (SMMT) · Wed 18 Nov 2026
NeOnc deck reports Phase 2a intranasal NEO100 results in recurrent IDH1-mutant glioma
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Wed 18 Nov 2026
Lantern Pharma opens first TNBC trial site, starts HARMONIC Part 2 in Taiwan; CEO resigns
🇺🇸 Lantern Pharma Inc. (LTRN) · Wed 18 Nov 2026
Optimi Health seeks to make psilocybin depression study randomised Phase 2b; MDMA Phase 3 planned
Optimi Health Corp. (OPTH) · Wed 18 Nov 2026